1 to 4 of 4 literature results

• Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.

  Lenalidomide and pomalidomide have both been evaluated clinically for their properties as anticancer agents, with lenalidomide being available commerc…

  Authors: Laure Escoubet-Lozach, I-Lin Lin, Kristen Jensen-Pergakes, Helen A Brady, Anita K Gandhi, Peter H Schafer, George W Muller, Peter J Worland, Kyle W H Chan, Dominique Verhelle

  Source: Cancer research. 2009 Sep 15

  View Full Text

• Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.

  Clinical studies involving patients with myelodysplastic syndromes or multiple myeloma have shown the efficacy of lenalidomide by reducing and often e…

  Authors: Dominique Verhelle, Laura G Corral, Kevin Wong, Jessica H Mueller, Laure Moutouh-de Parseval, Kristen Jensen-Pergakes, Peter H Schafer, Roger Chen, Emilia Glezer, Gregory D Ferguson,…

  Source: Cancer research. 2007 Jan 15

  View Full Text

• Circulating endothelial progenitor cells: a new approach to anti-aging medicine?

  Endothelial dysfunction is associated with major causes of morbidity and mortality, as well as numerous age-related conditions. The possibility of pre…

  Authors: Nina A Mikirova, James A Jackson, Ron Hunninghake, Julian Kenyon, Kyle W H Chan, Cathy A Swindlehurst, Boris Minev, Amit N Patel, Michael P Murphy, Leonard Smith,…

  Source: Journal of translational medicine. 2009

  View Full Text

• Modulation of cellular differentiation and cell fate for cancer therapy.

  Dysregulation of fundamental processes in developmental biology such as stem cell differentiation and proliferation may be the basis of many neoplasti…

  Authors: Laure A Moutouh-de Parseval, Kyle W H Chan

  Source: Current opinion in investigational drugs (London, England : 2000). 2004 Dec

  View Full Text